Biogen Inc.

LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026

New clinical and real-world data support a subcutaneous treatment pathway from initiation through maintenance treatment, offering dosing convenience for patients and care partners TOKYO and CAMBRIDGE, Mass., July 12, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc.

Biogen to Webcast from the Alzheimer's Association International Conference (AAIC) July 14, 2026

Cambridge, Mass.— Biogen Inc. (Nasdaq: BIIB) today announced it will hold an investor webcast on Tuesday, July 14, 2026, from the Alzheimer's Association International Conference (AAIC) in London. The Company will host a live webcast with Biogen management at 12:00 p.m. ET.

Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen

Diranersen presentation will feature Phase 2 CELIA data in early Alzheimer’s disease, including clinical, biomarker and safety results for Biogen’s investigational tau-targeting ASO, following topline results announced in May 2026 Lecanemab presentations will highlight emerging data on subcutaneous

Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.

Acquisition adds multiple immunology assets to Biogen’s portfolio, including a lead asset poised to enter Phase 1 development CAMBRIDGE, Mass. and SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and RayThera Inc., a private biotechnology company focused on discovering and

Biogen to Report Second Quarter 2026 Financial Results July 29, 2026

Cambridge, Mass.— Biogen Inc. (Nasdaq: BIIB) today announced it will report second quarter 2026 financial results Wednesday, July 29, 2026, before the financial markets open. Following the release of the financials, the Company will host a live webcast with Biogen management at 8:30 a.m. ET.

Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy

Designation is supported by an exploratory analysis from the Phase 1b study showing that some children with SMA previously treated with gene therapy who had suboptimal clinical status experienced slowing of neurodegeneration and clinically meaningful improvements in motor function following

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

Steroid use reduction and disease control: In additional results from the Phase 3 PHOENYCS GO study, dapirolizumab pegol (DZP) plus standard of care was associated with sustained disease control at lower glucocorticoid doses through Week 48 compared with placebo plus standard of care, supporting

Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses

Data presentations across multiple kidney diseases illustrate the breadth of Biogen’s nephrology portfolio with EMPAVELI® (pegcetacoplan) and felzartamab, an investigational anti-CD38 monoclonal antibody. CAMBRIDGE, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Biogen Inc.

UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus

Publication adds to previously reported findings from Phase 3 PHOENYCS GO study, demonstrating statistically significant improvement in disease activity at Week 48 with dapirolizumab pegol plus standard of care versus placebo plus standard of care Findings showed results in favor of dapirolizumab

Biogen Announces Webcast of Annual Meeting of Stockholders

Cambridge, Mass. – Biogen Inc. (Nasdaq: BIIB) announced today that the webcast of the Company's 2026 Annual Meeting of Stockholders will be held on Tuesday, June 9, 2026, at 9:00 a.m. Eastern Time. A live audio webcast of the meeting will be available on the Investor Relations section of the

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease

The Phase 2b LUMA study of BIIB122 in early-stage Parkinson’s disease did not meet its primary or secondary endpoints Based on data from the Phase 2b LUMA study, Biogen and Denali will discontinue development of BIIB122 in idiopathic Parkinson’s disease Denali continues to independently conduct the

Biogen Completes Acquisition of Apellis Pharmaceuticals

CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (Nasdaq: APLS). Apellis, a leader in advancing treatments for serious, complement-driven diseases, is now a wholly owned

Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease

CELIA did not meet its primary endpoint assessing dose response; based on the strength of the biomarker and efficacy data, Biogen plans to advance diranersen to registrational development Robust reductions in tau pathology were observed across all studied doses, with results generally consistent

Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease

TOKYO and CAMBRIDGE, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by three months for the supplemental Biologics License Application (sBLA) for a once-weekly

Biogen to Participate in the Bank of America Securities 2026 Health Care Conference

Cambridge, MA, - - Biogen Inc. (Nasdaq: BIIB) announced today that Adam Meyers, Head of Immunology and New Disease Areas Franchise, will participate in a fireside chat during the Bank of America Securities 2026 Health Care Conference. The webcast will be live on Wednesday, May 13, 2026, at 2:20

Biogen Reports First Quarter 2026 Results

Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region

With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights under one owner Advancing felzartamab – a CD38-directed antibody with potential broad applicability across a range of immune-mediated conditions – in the

Biogen to Report First Quarter 2026 Financial Results April 29, 2026

Cambridge, Mass.— Biogen Inc. (Nasdaq: BIIB) today announced it will report first quarter 2026 financial results Wednesday, Apr 29, 2026, before the financial markets open. Following the release of the financials, the Company will host a live webcast with Biogen management at 8:00 a.m. ET.

Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI ® FDA-approved in three indications, including two rare kidney diseases, and SYFOVRE ® FDA-approved in geographic atrophy, an immune-mediated retinal disease Bringing together Biogen and Apellis’

FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

The approval was anchored on data from the pivotal DEVOTE study that investigated the efficacy and safety of the High Dose Regimen of SPINRAZA in treatment-naïve and previously treated SPINRAZA patients High Dose SPINRAZA will be available in the United States in the coming weeks and is also

Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity

In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants achieving clear / almost clear skin Following positive Phase 2 LILAC results, litifilimab is the only

Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026

Real-World LEQEMBI Data Shows Patients Choose to Stay on Long-Term Treatment TOKYO and CAMBRIDGE, Mass., March 20, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO:

Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting

Late-breaking AMETHYST Part A study results to be presented, showing safety and efficacy of litifilimab in cutaneous lupus erythematosus (CLE) Litifilimab was recently granted Breakthrough Therapy Designation by the FDA for CLE; AMETHYST Part A results supported the designation CLE is a serious

Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy

New Phase 1b data support the safety and effectiveness of salanersen over one year in children with SMA who had the potential for improvement due to suboptimal clinical status with prior gene therapy Salanersen is a novel antisense oligonucleotide and has the potential to deliver high efficacy in

Biogen to Participate in the Stifel 2026 Virtual CNS Forum

Cambridge, MA, - - Biogen Inc. (Nasdaq: BIIB) announced today that Diana Gallagher, M.D., Head of Clinical Development, MS&I and AD, and Stephanie Fradette, PharmD, Head of the Neuromuscular Development Unit, will participate in a fireside chat during the Stifel 2026 Virtual CNS Forum.